190 related articles for article (PubMed ID: 36744372)
1. Formulation and evaluation of Piroxicam nanosponge for improved internal solubility and analgesic activity.
Gaber DA; Radwan MA; Alzughaibi DA; Alail JA; Aljumah RS; Aloqla RM; Alkhalifah SA; Abdoun SA
Drug Deliv; 2023 Dec; 30(1):2174208. PubMed ID: 36744372
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and Characterization of Curcumin-β-Cyclodextrin and Cyclodextrin-Based Nanosponge Inclusion Complexation.
Mashaqbeh H; Obaidat R; Al-Shar'i N
Polymers (Basel); 2021 Nov; 13(23):. PubMed ID: 34883577
[TBL] [Abstract][Full Text] [Related]
3. Enhancement in the therapeutic potential of lapatinib ditosylate against breast cancer by the use of β-cyclodextrin based ternary nanosponge system.
Tanaji Mane P; Sopanrao Wakure B; Shridhar Wakte P
Int J Pharm; 2023 Jul; 642():123210. PubMed ID: 37433350
[TBL] [Abstract][Full Text] [Related]
4. Ester-Based Hydrophilic Cyclodextrin Nanosponges for Topical Ocular Drug Delivery.
Hayiyana Z; Choonara YE; Makgotloe A; du Toit LC; Kumar P; Pillay V
Curr Pharm Des; 2016; 22(46):6988-6997. PubMed ID: 27981908
[TBL] [Abstract][Full Text] [Related]
5. Nano-Emulsion Based Gel for Topical Delivery of an Anti-Inflammatory Drug: In vitro and in vivo Evaluation.
Gaber DA; Alsubaiyel AM; Alabdulrahim AK; Alharbi HZ; Aldubaikhy RM; Alharbi RS; Albishr WK; Mohamed HA
Drug Des Devel Ther; 2023; 17():1435-1451. PubMed ID: 37216175
[TBL] [Abstract][Full Text] [Related]
6. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S
Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138
[TBL] [Abstract][Full Text] [Related]
7. Nanosponge formulations as oxygen delivery systems.
Cavalli R; Akhter AK; Bisazza A; Giustetto P; Trotta F; Vavia P
Int J Pharm; 2010 Dec; 402(1-2):254-7. PubMed ID: 20888402
[TBL] [Abstract][Full Text] [Related]
8. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study.
Ansari KA; Vavia PR; Trotta F; Cavalli R
AAPS PharmSciTech; 2011 Mar; 12(1):279-86. PubMed ID: 21240574
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of solubility enhancement, antioxidant activity, and cytotoxicity studies of kynurenic acid loaded cyclodextrin nanosponge.
Dhakar NK; Caldera F; Bessone F; Cecone C; Pedrazzo AR; Cavalli R; Dianzani C; Trotta F
Carbohydr Polym; 2019 Nov; 224():115168. PubMed ID: 31472867
[TBL] [Abstract][Full Text] [Related]
10. Solubility and dissolution rate enhancement of ibuprofen by cyclodextrin based carbonate nanosponges.
Shoaib QU; Latif S; Ijaz QA; Afzal H; Siddique MI; Hussain A; Arshad MS; Bukhari NI; Abbas N
Pak J Pharm Sci; 2021 May; 34(3(Supplementary)):1045-1055. PubMed ID: 34602431
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of solubility, dissolution release profile and reduction in ulcerogenicity of piroxicam by inclusion complex with skimmed milk.
Sanka K; Munjulury VS; Mohd AB; Diwan PV
Drug Deliv; 2014 Nov; 21(7):560-70. PubMed ID: 24266528
[TBL] [Abstract][Full Text] [Related]
12. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam.
Prajapati RN; Tekade RK; Gupta U; Gajbhiye V; Jain NK
Mol Pharm; 2009; 6(3):940-50. PubMed ID: 19231841
[TBL] [Abstract][Full Text] [Related]
13. Solid-state, triboelectrostatic and dissolution characteristics of spray-dried piroxicam-glucosamine solid dispersions.
Adebisi AO; Kaialy W; Hussain T; Al-Hamidi H; Nokhodchi A; Conway BR; Asare-Addo K
Colloids Surf B Biointerfaces; 2016 Oct; 146():841-51. PubMed ID: 27451373
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of Bioavailability of Non-nucleoside Reverse Transciptase Inhibitor Using Nanosponges.
Rao MRP; Shirsath C
AAPS PharmSciTech; 2017 Jul; 18(5):1728-1738. PubMed ID: 27757921
[TBL] [Abstract][Full Text] [Related]
15. Weak complexation of 5-fluorouracil with β-cyclodextrin, carbonate, and dianhydride crosslinked β-cyclodextrin:
Mashaqbeh H; Obaidat R; Al-Shar'i NA; El-Elimat T; Alnabulsi S
Res Pharm Sci; 2022 Aug; 17(4):334-349. PubMed ID: 36034082
[TBL] [Abstract][Full Text] [Related]
16. [Analgesic efficacy and the tolerance for piroxicam-beta-cyclodextrin compared to piroxicam, paracetamol and placebo in the treatment of postextraction dental pain].
Dolci G; Ripari M; Pacifici L; Umile A
Minerva Stomatol; 1993 May; 42(5):235-41. PubMed ID: 8413108
[TBL] [Abstract][Full Text] [Related]
17. Nanodispersions stabilized by β-cyclodextrin nanosponges: application for simultaneous enhancement of bioactivity and stability of sage essential oil.
Nait Bachir Y; Nait Bachir R; Hadj-Ziane-Zafour A
Drug Dev Ind Pharm; 2019 Feb; 45(2):333-347. PubMed ID: 30388376
[TBL] [Abstract][Full Text] [Related]
18. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.
Shende PK; Gaud RS; Bakal R; Patil D
Colloids Surf B Biointerfaces; 2015 Dec; 136():105-10. PubMed ID: 26364091
[TBL] [Abstract][Full Text] [Related]
19. Cyclodextrin-based nanosponge for improvement of solubility and oral bioavailability of Ellagic acid.
Mady FM; Ibrahim SR
Pak J Pharm Sci; 2018 Sep; 31(5(Supplementary)):2069-2076. PubMed ID: 30393214
[TBL] [Abstract][Full Text] [Related]
20. Design and formulation of polymeric nanosponge tablets with enhanced solubility for combination therapy.
Moin A; Roohi NKF; Rizvi SMD; Ashraf SA; Siddiqui AJ; Patel M; Ahmed SM; Gowda DV; Adnan M
RSC Adv; 2020 Sep; 10(57):34869-34884. PubMed ID: 35514416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
